title: Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction.
abstract: Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive anterior infarction and severe ventricular dysfunction. The malignant ventricular tachyarrhythmia was effectively suppressed at a relatively low dose, without compromising the hemodynamics, indicating that this potent K+ channel blocker has therapeutic potential for acute myocardial infarction.
authors.affiliation: Division of Cardiology, Department of Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Takenaka
authors.forename: S
authors.initials: S
authors.lastname: Yasuda
authors.forename: S
authors.initials: S
authors.lastname: Miyazaki
authors.forename: T
authors.initials: T
authors.lastname: Kurita
authors.forename: Y
authors.initials: Y
authors.lastname: Sutani
authors.forename: I
authors.initials: I
authors.lastname: Morii
authors.forename: S
authors.initials: S
authors.lastname: Daikoku
authors.forename: S
authors.initials: S
authors.lastname: Kamakura
authors.forename: H
authors.initials: H
authors.lastname: Nonogi
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000592:standards; D004562:Electrocardiography; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000628:therapy; D026902:Potassium Channel Blockers; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000592:standards; D013610:Tachycardia / Q000188:drug therapy; D018754:Ventricular Dysfunction / Q000188:drug therapy* / Q000628:therapy
chemical_list: D000889:Anti-Arrhythmia Agents; D026902:Potassium Channel Blockers; D011744:Pyrimidinones; C076259:nifekalant